Changes of fibrotic proteins in rat peritoneum. by Yangyang Yin (14323701)

Subjects:

Changes of miR-132-3p in peritoneal dialysis patients with different duration. by Yangyang Yin (14323701)

Subjects:

Regulation of TGF-<i>β</i>1 protein expression by MiR-132-3p was verified using WB. by Yangyang Yin (14323701)

Subjects:

Changes of peritoneal structure and function in rats. by Yangyang Yin (14323701)

Subjects:

Cardiac inflammatory parameters. by Taynara Aparecida Vieira (16401726)

Subjects:

The effect of MiR-132-3p on protein expression in TGF-<i>β</i>1/Smad2/3 signaling pathway was observed by immunofluorescence. by Yangyang Yin (14323701)

Subjects:

Comparison of detection results between YOLOv5s and P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

The differences between WKY and SHR responses to betaine. by Izabella Mogilnicka (13965422)

Supplementary Material for: Fasting blood glucose: A mediator of the association between estimated glomerular filtration rate and arterial stiffness in Japanese population with dec... by Wu L. (4145662)

“…The mean values for FBG, eGFR and baPWV were 5.46 ± 0.79 mmol/L, 68.83 ± 10.05 mL/min/1.73m², and 1423.50 ± 247.78 cm/s, respectively. …”

Serum samples and 50% NAI values. Serum samples taken from CEIRS study. by Harrison Powell (9040128)

Effects of betaine on diuresis [μl/min/g k.w.], HR [bpm] and MABP [mmHg] in anesthetized Spontaneously Hypertensive rats and Wistar Kyoto normotensive rats. by Izabella Mogilnicka (13965422)

Primary pharmacokinetic parameters of paclitaxel in rats after intravenous administration of Taxol, Abraxane, or self-made nanoparticles at a paclitaxel dose of 7mg/kg (<i>n</i> =... by Yue Gao (263086)

Random forest model variable importance ranking by mean decrease in Gini value in the derivation dataset (<i>N</i> = 2,771). by Andrew F. Auld (8967719)

Flowchart of study selection. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

Subjects:

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects: